Theravance Biopharma Inc (TBPH) was Downgraded by Robert W. Baird to ” Underperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 24 from a previous price target of $19 . Earlier the firm had a rating of “Neutral ” on the company shares. Robert W. Baird advised their investors in a research report released on Oct 12, 2016.
Many Wall Street Analysts have commented on Theravance Biopharma Inc. Theravance Biopharma Inc was Downgraded by BofA/Merrill to ” Underperform” on Aug 3, 2016.
Theravance Biopharma Inc closed down -1.14 points or -2.95% at $37.44 with 1,84,348 shares getting traded on Tuesday. Post opening the session at $38.25, the shares hit an intraday low of $36.6 and an intraday high of $38.53 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Aug 25, 2016, Brett K Haumann (SVP Clin Dev & Chief Med Ofc) sold 4,491 shares at $27.99 per share price. According to the SEC, on Aug 22, 2016, Bradford J Shafer (EVP, Gen. Counsel, Secretary) sold 49,122 shares at $27.95 per share price. On Aug 18, 2015, Junning Lee (Sr. VP, Technical Operations) purchased 9,000 shares at $12.90 per share price, according to the Form-4 filing with the securities and exchange commission.
Theravance Biopharma Inc. (Theravance Biopharma) is a biopharmaceutical company. The Company is engaged to create value from a diverse set of assets: an approved product; a development pipeline of mid- and late-stage assets and a productive research platform designed for long-term growth. VIBATIV (telavancin) its commercial product is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. TD-4208 is an investigational long-acting muscarinic antagonist (LAMA) being developed as a potential once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD). Axelopran (TD-1211) is an investigational potential once-daily oral treatment for opioid-induced constipation (OIC). Its earlier-stage clinical assets represent approaches for potentially treating diseases of the lung and gastrointestinal tract and infectious disease.